Analyst Ratings For La Jolla Pharmaceutical (NASDAQ:LJPC) (NASDAQ:LJPC)
Today, HC Wainwright lowered its price target on La Jolla Pharmaceutical (NASDAQ:LJPC) (NASDAQ:LJPC) to per share.
Some recent analyst ratings include
- 2/12/2018-Jefferies Group was Downgraded by analysts at Jefferies Group from a “Buy ” rating to a ” Underperform” rating. They now have a $29.00 price target on the stock, up previously from $40.00 .
- 12/22/2017-Cowen Reiterated Rating of Buy.
- 12/22/2017-JPMorgan Chase & Co. Reiterated Rating of Sell.
- 4/30/2017-Noble Financial Reiterated Rating of Buy.
- On 3/15/2018 Kevin C Tang, Director, bought 508,474 with an average share price of $29.50 per share and the total transaction amounting to $14,999,983.00.
- On 3/2/2018 Kevin C Tang, Director, bought 10,000 with an average share price of $30.44 per share and the total transaction amounting to $304,400.00.
- On 2/27/2018 Kevin C Tang, Director, bought 150,000 with an average share price of $31.82 per share and the total transaction amounting to $4,773,000.00.
- On 2/23/2018 Jennifer Carver, COO, bought 1,000 with an average share price of $32.48 per share and the total transaction amounting to $32,480.00.
- On 2/14/2018 Life Sciences Maste Perceptive, Major Shareholder, bought 175,000 with an average share price of $32.72 per share and the total transaction amounting to $5,726,000.00.
- On 12/29/2017 Laura L Douglass, Director, sold 10,000 with an average share price of $32.32 per share and the total transaction amounting to $323,200.00.
- On 12/29/2017 Laura L Douglass, Director, sold 10,000 with an average share price of $32.32 per share and the total transaction amounting to $323,200.00.
Recent Trading Activity for La Jolla Pharmaceutical (NASDAQ:LJPC) (NASDAQ:LJPC)
Shares of La Jolla Pharmaceutical (NASDAQ:LJPC) closed the previous trading session at 28.85 up +0.33 1.16% with 59698 shares trading hands.
